Medication info

Ibandronate Sodium Injection (Ibandronate Sodium Monohydrate)

Prescription medicationExpired
Ingredient · strength
Ibandronate Sodium Monohydrate›Strength being verified
Manufacturer / importer
Vive Herbal Co., Ltd.
Appearance
This is an injectable solution that is colorless and transparent, contained in a colorless and transparent glass prefilled syringe, with a single-use injection needle attached.
Packaging
3mL x 1 vial
Approval status
Expired

MFDS item code 201802102 · Notified 2018.05.18

This product's status changed to Expired on 2023.05.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who uses it
Adults · Children
Adult dosage
Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible, and continue regular dosing at 3-month intervals thereafter. Patients with hepatic impairment No dose adjustment is required. Patients with renal impairment No dose adjustment is required for patients with mild or moderate renal impairment with serum creatinine of 200 µmol/L(2.3mg/dL) or lower, or creatinine clearance of 30ml/min or higher. Use of this medication is not recommended in patients with serum creatinine exceeding 200 µmol/L(2.3mg/dL) or creatinine clearance below 30ml/min, as there is insufficient clinical experience. Elderly patients No dose adjustment is required.
Children's dosage
The efficacy and safety in children under 18 years of age have not been studied.

Ingredients

Manufacturer
Vive Herbal Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used to treat osteoporosis in postmenopausal women. After menopause, women tend to lose bone density and suffer from weak bones due to decreased estrogen levels, which can increase the risk of fractures. This medication helps prevent bone loss and increase bone density to reduce the risk of fractures. With regular administration, it helps maintain bone health and allows for more stable daily living. Therefore, it is used for the treatment of osteoporosis in postmenopausal women.

Dosage and Administration

Adult dosage

Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible, and continue regular dosing at 3-month intervals thereafter. Patients with hepatic impairment No dose adjustment is required. Patients with renal impairment No dose adjustment is required for patients with mild or moderate renal impairment with serum creatinine of 200 µmol/L(2.3mg/dL) or lower, or creatinine clearance of 30ml/min or higher. Use of this medication is not recommended in patients with serum creatinine exceeding 200 µmol/L(2.3mg/dL) or creatinine clearance below 30ml/min, as there is insufficient clinical experience. Elderly patients No dose adjustment is required.

Children's dosage

The efficacy and safety in children under 18 years of age have not been studied.

Precautions

This medication must be administered intravenously; caution is necessary to avoid tissue damage if administered intramuscularly or around the veins. It should not be used in patients with allergies to this drug or its components, or in patients with untreated hypocalcemia. During treatment, gastrointestinal adverse reactions such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, and constipation may occur. Musculoskeletal side effects may include myalgia, arthralgia, and musculoskeletal pain; systemic and skin reactions such as flu-like symptoms, fatigue, headache, and rash have also been reported. Initial administration may temporarily cause flu-like symptoms, although these are usually mild and resolve without treatment. This medication can temporarily lower serum calcium levels, so hypocalcemia or bone and mineral metabolism disorders should be treated before administration, and calcium and vitamin D intake must be adequate. Patients undergoing dental treatment or with a risk of osteonecrosis of the jaw should undergo an oral examination before administration and should ideally avoid dental procedures during treatment. Long-term use of this medication may increase the risk of atypical femoral fractures, so immediate consultation with healthcare professionals is warranted if experiencing thigh or groin pain. Since this medication is not metabolized in the liver and is primarily excreted through the kidneys, patients with impaired renal function require regular monitoring. It is recommended that pregnant or nursing women avoid this medication, and the safety and efficacy in pediatric patients under 18 years old have not been established. Overdose may cause toxicity to the kidneys and liver, necessitating appropriate treatment for hypocalcemia and other conditions. This medication should not be mixed with calcium-containing solutions or other intravenous medications and must be administered intravenously as a single agent. After use, do not reuse the injection needle and syringe; discard them in a safe container and store out of reach of children.

Side effects

Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reaction, phlebitis, thrombophlebitis, hypersensitivity reaction, angioedema, facial swelling, edema, hives, uveitis, episkleritis, scleritis, anaphylactic reaction, shock, asthma exacerbation, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical electronic bone fracture, osteonecrosis, osteonecrosis of the jaw, osteonecrosis of the external auditory canal, acute renal failure, sensory loss, dizziness, hearing loss, dyspnea, skin exfoliation, multiple organ failure, death, fever, hypothyroidism, peripheral motor neuropathy, insomnia, anxiety, tinnitus, lipoma, ocular hemorrhage, heart failure, urinary disorders, hematuria, optic nerve atrophy, lower motor neuron lesions, tremor, unspecified gastrointestinal disorder, benign gastrointestinal neoplasm, toothache, hyperventilation, cough, laryngitis, vaginitis, menopausal symptoms

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air and moisture exposure, ideally at room temperature between 1 and 30 degrees Celsius. Proper storage will maintain the medication's efficacy and prevent degradation.

Appearance and packaging

Appearance

This is an injectable solution that is colorless and transparent, contained in a colorless and transparent glass prefilled syringe, with a single-use injection needle attached.

Package unit

3mL x 1 vial

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.